Women with non‐ST‐elevation acute coronary syndromes remain understudied and undertreated
Ischaemic heart disease is the leading cause of death for women worldwide, and sex‐related disparities continue to characterise its management.1 Despite initiatives addressing this problem, cardiovascular risk in women is still underestimated and guideline recommendations have failed to develop sex‐specific strategies, primarily because women are underrepresented in clinical trials.1,2,3 In particular, sex‐specific pathophysiological mechanisms of ischaemic heart disease have not been fully elucidated; for example, acute coronary syndromes (ACS) are more frequently associated with non‐obstructive coronary artery disease and spontaneous coronary dissection in women than in men.4,5 Further, the symptoms of myocardial infarction may be different in women, and this contributes to its under‐recognition and, ultimately, to delays in appropriate treatment.6
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
Roxana Mehran has received institutional research grants from Abbott, Abiomed, Applied Therapeutics, Arena, AstraZeneca, Bayer, Biosensors, Boston Scientific, Bristol‐Myers Squibb, CardiaWave, CellAegis, CERC, Chiesi, Concept Medical, CSL Behring, DSI, Insel Gruppe, Medtronic, OrbusNeich, Philips, Transverse Medical, and Zoll; personal fees from ACC, Boston Scientific, California Institute for Regenerative Medicine (CIRM), Cine‐Med Research, Janssen, WebMD, and SCAI; consulting fees (paid to her institution) from Abbott, Abiomed, AM‐Pharma, Alleviant Medical, Bayer, Beth Israel Deaconess, CardiaWave, CeloNova, Chiesi, CSL Behring, Concept Medical, DSI, Duke University, Idorsia Pharmaceuticals, Medtronic, Novartis, and Philips; and has equity (less than 1%) in Applied Therapeutics, Elixir Medical, and STEL, and her spouse has similarly minor equity in CONTROLRAD. She sits on the scientific advisory boards for the American Medical Association and the Cardiovascular Research Foundation (no fee); her spouse sits on the Biosensors scientific advisory board.